Alto Neuroscience (ANRO) Gains from Investment Securities (2023 - 2026)
Alto Neuroscience's (ANRO) quarterly Gains from Investment Securities came in at $190000.0 in Q1 2026, up 563.41% year-on-year from $28639.7 in Q1 2025, and up 21.79% quarter-over-quarter from $156000.0 in Q4 2025.
Alto Neuroscience (ANRO) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Alto Neuroscience has disclosed Gains from Investment Securities across 4 years of filings, most recently posting $190000.0 for Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $190000.0, up 563.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $231000.0 (up 104.33% YoY), and the FY2024 annual result was -$52000.0, changed N/A from the prior year.
- Gains from Investment Securities came in at $190000.0 for Q1 2026 at Alto Neuroscience, up from $156000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $243000.0 in Q1 2024 to a low of -$5.3 million in Q4 2024.
- The 4-year median for Gains from Investment Securities is -$26000.0 (2023), against an average of -$522400.0.
- Across the five-year window, Gains from Investment Securities jumped 2309.09% in 2024 and sank 116.87% in 2025, its largest moves.
- Alto Neuroscience's Gains from Investment Securities stood at -$226000.0 in 2023, then tumbled by 2244.25% to -$5.3 million in 2024, then soared by 102.94% to $156000.0 in 2025, then climbed by 21.79% to $190000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $190000.0 (Q1 2026), $156000.0 (Q4 2025), and -$114000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Alto Neuroscience | 643.06 Mn | 379.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 190,000.00 |
| Mar 31, 2026 | 190,000.00 |
| Dec 31, 2025 | 156,000.00 |
| Dec 31, 2025 | 156,000.00 |
| Sep 30, 2025 | -114,000.00 |
| Sep 30, 2025 | -114,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | -41,000.00 |
| Mar 31, 2025 | -41,000.00 |
| Dec 31, 2024 | -5.30 Mn |
| Dec 31, 2024 | -5.30 Mn |
| Mar 31, 2024 | 243,000.00 |
| Mar 31, 2024 | 243,000.00 |
| Sep 30, 2023 | -226,000.00 |
| Sep 30, 2023 | -226,000.00 |
| Jun 30, 2023 | -122,000.00 |
| Jun 30, 2023 | -122,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Mar 31, 2023 | -11,000.00 |